Practice facilitation for improving cardiovascular care: secondary evaluation of a stepped wedge cluster randomized controlled trial using population-based administrative data by unknown
RESEARCH Open Access
Practice facilitation for improving
cardiovascular care: secondary evaluation
of a stepped wedge cluster randomized
controlled trial using population-based
administrative data
Catherine Deri Armstrong1*, Monica Taljaard2,3, William Hogg4,5,6, Amy E. Mark6,7 and Clare Liddy4,5
Abstract
Background: Practice facilitation (PF), a multifaceted approach in which facilitators (external health care professionals)
help family physicians to improve their adoption of best practices, has been highly successful. Improved Delivery of
Cardiovascular Care (IDOCC) was an innovative PF trial designed to improve evidence-based care for people who have,
or are at risk of, cardiovascular disease (CVD). The intervention was found to be ineffective as assessed by a patient-level
composite score based on chart reviews from a subsample of patients (N = 5292). Here, we used population-based
administrative data to examine IDOCC’s effect on CVD-related hospitalizations.
Methods: IDOCC used a pragmatic, stepped wedge cluster randomized controlled design involving primary care
providers recruited across Eastern Ontario, Canada. IDOCC’s effect on CVD-related hospitalizations was assessed in the
2 years of active intervention and post-intervention years. Marginal and mixed-effects regression analyses were used to
account for the study design and to control for patient, physician, and practice characteristics. Secondary and subgroup
analyses investigated robustness.
Results: Our sample included 262,996 patient/year observations representing 54,085 unique patients who had, or were
at risk of, CVD, from 70 practices. There was a strong decreasing secular trend in CVD-related hospitalizations but no
statistically significant effect of IDOCC. Relative to patients in the control condition, patients in the intervention
condition were estimated to have 4 % lower odds of CVD-related hospitalizations (adjOR = 0.96, 99 % CI 0.83 to 1.11).
The nonsignificant result persisted across robustness analyses.
Conclusions: Clinical outcomes from administrative databases were examined to form a more complete picture of
the (in)effectiveness of a large-scale quality improvement intervention. IDOCC did not have a significant effect on CVD
hospitalizations, suggesting that the results from the primary composite adherence score analysis were neither due to
choice of outcome nor relatively short follow-up period.
Trial registration: ClinicalTrials.gov NCT00574808, registered on 14 December 2007.
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Background
Practice facilitation (PF) is an approach designed to im-
prove the uptake of evidence-based best practices in pri-
mary care [1]. It involves bringing external health care
professionals into a practice to help identify areas for
improvement, set improvement goals, and provide tools
and approaches to reach these goals. Numerous studies
have associated PF with improvements in prevention,
diabetes care, smoking cessation, and cancer care [2–5].
PF has become popular as evidenced by its broad imple-
mentation worldwide [1, 6]. Still, some aspects of PF re-
main poorly understood [1, 2, 5, 7–9]. More research is
needed to explore the impact of PF programs targeting
multiple diseases, to examine its effectiveness across dif-
ferent professional settings, and to identify the ideal inten-
sity of intervention (i.e., number of sessions a practice
should receive).
The Improved Delivery of Cardiovascular Care (IDOCC)
project was an innovative, multifaceted quality improve-
ment trial designed to assist primary care providers in im-
proving their delivery of evidence-based care for patients
who have, or are at risk of, cardiovascular disease (CVD)
[10]. The 2-year intervention involved sending external
outreach facilitators (in this case, specially trained nurses)
into participating family medicine practices monthly in the
first year and less frequently (every 6–12 weeks) in the
second year.
The registered primary outcome of the trial was a
composite score assessing physicians’ adherence to rec-
ommended care guidelines. This outcome was assessed
using chart audit data for approximately 66 randomly se-
lected patients who had, or were at risk of, CVD in each
practice. The intervention was found to decrease adher-
ence to evidence-based guidelines (i.e., worsened care)
by a statistically significant, but clinically unimportant,
amount [11]. These results sharply contrast with find-
ings of previous facilitation trials [5, 12–14].
In that study, annual chart audits ended in the final
intervention year – meaning that a slower uptake of best
practices could not be captured in the analysis. Here, we
used population-based administrative databases to link
IDOCC participants to routinely collected clinical out-
comes in all study years (pre-intervention, two interven-
tion years, and post-intervention) in order to provide a
more complete picture of the potential effect of IDOCC,
focusing on CVD-related hospitalizations.
Methods
Setting
Facilitation visits took place between 14 April 2008 and 27
March 2012 in the Champlain Local Health Integration
Network (LHIN) of Eastern Ontario, Canada, a diverse re-
gion of 1.2 million individuals with disease burdens and
health outcomes comparable to the rest of the province
and country. A complete protocol of the IDOCC study
has been published elsewhere [10]. We provide an over-
view of the methods as per the Consolidated Standards
of Reporting Trials (CONSORT) checklist [15] (see
Additional file 1).
Study design
IDOCC followed a stepped wedge cluster randomized
controlled design utilizing three distinct study groups, or
“steps.” Practices were allocated to steps by region and
each step sequentially started the intervention a year
apart (see Fig. 1).
To randomize practices, the LHIN was first divided into
nine geographic regions using Geographic Information
Fig. 1 The Improved Delivery of Cardiovascular Care (IDOCC) stepped wedge study design used in the analysis of clinical outcomes using
population-based health administrative data. Legend: the darker nonstriped cells indicate IDOCC intervention years and the striped cells indicate
post-IDOCC years where patients may still be benefitting from the intervention. Blank cells represent control periods
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System mapping technology, and then grouped into three
strata (west, central, and east) using computer-generated
random numbers provided by an independent statistician.
Within each stratum, the regions were randomly assigned
to one of three study steps. Thus, each step comprised
participating practices from three of the nine regions, one
from the east, central, and west.
The stepped wedge design was chosen to (1) minimize
the practical, logistical, and financial constraints associ-
ated with large-scale project implementation, (2) control
for any secular trend in CVD hospitalization rates, and
(3) ensure that all practices eventually received the inter-
vention [16]. The trial concluded at the end of the inter-
vention phase for step 3 practices, as scheduled. The
Ottawa Hospital Research Ethics Board approved this
trial (2007292-01H).
Recruitment
Invitations to participate were sent to all practices in the
LHIN that (1) were in operation for 2 years prior to 2008,
and (2) offered general primary care services. Consent was
obtained from all participating physicians. Participants re-
ceived no financial compensation, though could receive
continuing professional development credits. All partici-
pants agreed to have their data identified within the Insti-
tute for Clinical Evaluative Sciences (ICES), the research
institute that houses the administrative data. Details on
the recruitment strategy have been published elsewhere
[10]. Patient consent was not required as the intervention
did not directly target patients, and no identifiable infor-
mation was collected from patients; all analyses were con-
ducted in securely held databases within ICES [17].
Dataset creation
Datasets were linked using unique encoded patient and
physician identifiers and analyzed at ICES. An Appendix
containing additional information regarding data linkage
and construction as well as all codes from the Inter-
national Classification of Diseases (ICD) used in identify-
ing patients with CVD and CVD-related hospitalizations
is available separately (see Additional file 2).
To construct the sample of patients targeted by IDOCC,
we first created a patient roster for each physician for each
year (2005 to 2012). Patients officially rostered to a phys-
ician for capitation payment reasons were identified using
the Client Agency Program Enrollment database. Patients
not formally enrolled to a family physician were “virtually”
attributed to the family physician who has billed (or
“shadow billed” in capitation and salaried models) the lar-
gest dollar amount of services over a 2-year period. This
information is available in the Ontario Health Insurance
Plan claims database. This “virtual rostering” approach
has been used in other studies and is the accepted report-
ing approach for Ontario’s Ministry of Health and Long-
Term Care reports [18, 19]. Physician characteristics (sex,
years since graduation, and indicator for being trained
abroad) and practice characteristics (remuneration model
type, rurality indicator, and practice group size) were ob-
tained from the ICES Physician Database.
Next, we identified all patients within each roster who
had, or were at risk of, CVD. Using validated algorithms,
we identified patients aged 40 years and over who had
coronary artery disease, cerebral vascular disease (to
capture transient ischemic attack and stroke), diabetes,
renal failure, or peripheral vascular disease. Patients at
risk of CVD were identified as men aged 45 or older or
women aged 55 years or older with hypertension. Patient
characteristics (age, sex, number of Aggregated Diagnosis
Groups (ADGs), rurality, income quintile and immi-
grant status) were obtained from the Registered Per-
sons Database and Postal Code Conversion File. Johns
Hopkins ADGs measure patients’ comorbidity. Based
on their health care utilization in the previous 2 years,
patients are attributed between zero and 32 ADGs, with
greater number of ADGs indicating greater comorbid-
ity. Each ICD code is assigned to one of the 32 ADGs
based on five clinical dimensions: duration, severity and
etiology of the condition, diagnostic certainty, and spe-
cialty care involvement [20].
Outcome measure
The clinical outcome of interest was a patient-level di-
chotomous indicator of any hospital admission for CVD
in the fiscal year (April–March) and was constructed
from information in the Discharge Abstract Database.
The reason for hospitalization was identified using the
ICD10-CA codes listed under the hospitalization’s “Most
Responsible Diagnosis” (see Additional file 2 for the list
of ICD codes used to identify the various CVDs). The
outcome was assessed cross-sectionally using all eligible
patients in each study year (2005–2012).
Sample size
The sample size for the IDOCC study was determined
based on the primary process measure for the trial (ad-
herence) as presented elsewhere [11]. For this secondary
analysis, the clinical outcome was assessed in all partici-
pating practices using population-level data, and no add-
itional a-priori sample size calculation was carried out.
Data analysis
The number and percentage of patients with each of the
five cardiovascular diseases and who were considered “at
risk” is reported by study year. “Baseline” descriptive sta-
tistics summarizing practice and patient characteristics
in 2007, the year before the first set of practices received
the intervention, are reported by step. CVD hospitaliza-
tions were analyzed at the individual patient level using
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generalized linear mixed effects regression with logit link
function and binomial distribution, estimated using re-
sidual pseudo-likelihood in SAS v.9.3. Region (unit of
randomization), time, and treatment were specified as
fixed effects, while practices and providers were specified
as random effects to account for multiple levels of clus-
tering of patients within providers and practices. Treat-
ment was defined as a three-level categorical variable to
allow for control, intervention (2 years of active inter-
vention), and post-intervention conditions, while time
was modelled as a simple linear term after visual inspec-
tion of empirical logit plots of the observed trends in
hospitalization. The statistical significance of the inter-
vention was assessed using approximated Wald F-tests
with denominator degrees of freedom estimated using
the between-within method [21]. Pairwise differences
among the three intervention conditions were calculated,
expressed as odds ratios (OR) with 99 % confidence inter-
vals (CIs). The unadjusted analysis was followed by two
adjusted analyses: the first controlling for patient charac-
teristics and the second controlling for patient, physician,
and practice characteristics.
Three additional analyses were performed to gauge ro-
bustness of the results. First, CVD hospitalizations were
measured as an annual count as opposed to a dichotom-
ous outcome and analyzed using negative binomial dis-
tribution and log link function. Due to failure of the
mixed-effects model to converge, a marginal model using
generalized estimating equations (GEE) was used with ro-
bust standard errors and an exchangeable correlation
structure to account for clustering of patients within prac-
tices. Results from the marginal model are presented using
relative risk (RR) with 99 % CI for pairwise comparisons.
The second robustness specification restricted the sam-
ple to patients with diabetes. This subgroup was chosen
for three reasons: (1) patients with diabetes in the health
utilization datasets can be identified very accurately, de-
creasing possible measurement error, (2) patients with
diabetes comprise the largest diagnosis group in our sam-
ple, and (3) the majority of practices were working with
the facilitators on diabetes-related issues. The third ro-
bustness specification included only individuals from the
sample who had diagnosed CVD; individuals identified as
“at risk” were excluded to assess sensitivity to potential
misclassification of this group due to the known limita-
tions of health administrative data. The model for the sec-
ond and third robustness analyses were as described for
the main model.
Results
Of the 434 eligible practices, 93 (comprising 194 physi-
cians) agreed to participate in IDOCC. Ten practices
withdrew from the study prior to the initiation of the
intervention. Twelve of the participating practices were
community health centers and were excluded from this
analysis, as reliable information on this practice model is
only available within ICES from 2008 onward. Two prac-
tices were long-term care facilities served by the same
family physician and, thus, collapsed into a single loca-
tion for practical purposes. Other challenges we faced in
creating linkages included an inability to create a virtual
roster for physicians who took eight or more consecutive
weeks away from work and a lack of billing data. After
accounting for these exclusions, we were able to success-
fully link to the outcomes of patients in 70 practices
(comprising 129 physicians). The total number of pa-
tients linked each year for analysis ranged from 26,042
to 37,050, with almost half (47.8 to 51.5 %) being identi-
fied as at risk of CVD (Table 1).
The baseline descriptive data are presented in Table 2.
While similar numbers of practices were included in
each step (22 in step 1 and 24 in steps 2 and 3), there
were substantial differences across steps with respect to
practice and patient characteristics. Step 1 practices had
the lowest prevalence of female doctors (40 % versus
64 % in step 2) and the highest prevalence of being lo-
cated in a rural area (37 % versus <5 % in step 2), and
were almost exclusively fee-for-service (as compared to
approximately 50 % in steps 2 and 3). Patients from step
1 practices were most commonly rural (39 % versus 5 %
for step 3) and had the highest number of annual hos-
pital admissions for CVD in 2007.
The observed trends in CVD hospitalization rates are
presented in Fig. 2. There were differences in the levels
of hospitalizations across steps, but a similar decreasing
secular trend. The results from the mixed-effects logistic
regression analysis with and without adjustment for co-
variates are presented in Table 3. The analysis included
262,996 observations representing 54,085 unique pa-
tients. The effect of the intervention was not statistically
significant (p = 0.78 in the unadjusted and p = 0.67 in the
fully adjusted model). Pairwise least square mean differ-
ences in hospitalization proportions between intervention
conditions are presented in Table 4 panel a. Estimates ob-
tained from analyses adjusting for patient, provider, and
practice characteristics were similar to those from un-
adjusted analyses. On average, patients in the intervention
condition had a 4 % lower odds of any CVD hospitaliza-
tions relative to the control condition (adjOR = 0.96, 99 %
CI 0.83 to 1.11), and a 7 % lower odds in the post-
intervention condition relative to control (adjOR = 0.93,
99 % CI 0.74 to 1.15), though neither difference was statis-
tically significant (p = 0.49 and p = 0.36 respectively).
Tables 4 panels b, c and d present the results from our
robustness analyses. Modeling the outcome as a count
(Table 4 panel b) indicated statistically insignificant esti-
mates of effectiveness: a 5 % reduction in adjusted risk
of one additional CVD hospitalization in an intervention
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year versus baseline (RR = 0.95, 99 % CI 0.83 to 1.09, p =
0.46) and a 7 % reduction in a post-intervention year ver-
sus baseline (RR = 0.93, 99 % CI 0.71 to 1.21, p = 0.56).
Both approaches led to the same conclusion: no statisti-
cally significant effect of IDOCC on CVD hospitalizations.
The final two robustness checks restrict the sample to pa-
tients with diabetes (Table 4 panel c) and then to patients
with diagnosed CVD (excluding those only at risk) (Table 4
panel d). In no case was IDOCC found to have had any
meaningful effect on CVD hospitalizations.
Table 2 Comparison of practice, provider, and patient characteristics at baseline (2007) by Step
Characteristic Step 1 Step 2 Step 3
Practice
Number of practices (n) 22 24 24
Provider
Number of providers (n) 30 63 36
Female (n, %) 12 (40.0 %) 40 (63.5 %) 21 (58.3 %)
Years since graduation from 2007 (mean, SD) 25.5 (9.9) 18.9 (9.2) 24.1 (10.1)
Primary care model (n)
Fee for service 25–29 26 19
Capitation, non-FHT 1–5 23 10–14
Capitation, FHT 0 14 1–5
Rural practices (n, %) 11 (36.7 %) 1–5 (1.0–5.0 %) 11 (30.6)
Patient
Number of patients (n) 7830 12,819 9659
Age (mean, SD) 67.9 (12.7) 65.0 (11.9) 66.9 (12.0)
Female (n, %) 4069 (52.0 %) 6669 (52.0 %) 5074 (52.5 %)
Number of Aggregated Diagnostic Groups (mean, SD) 7.1 (3.7) 6.8 (3.5) 6.7 (3.6)
Rural residents (n, %) 3071 (39.2 %) 618 (4.8 %) 2558 (26.5 %)
FHT Family Health Team
Table 1 Number and percentage of eligible patients at risk of, and with, cardiovascular disease (CVD) by year and type of chronic
condition
2005 2006 2007 2008 2009 2010 2011 2012
Total number of patients 26,042 28,196 30,308 32,901 34,898 36,610 37,050 36,991
At risk of CVD 13,424 14,500 15,241 16,312 17,211 17,817 17,797 17,671
(51.5 %) (51.4 %) (50.3 %) (49.6 %) (49.3 %) (48.7 %) (48.0 %) (47.8 %)
Patients with CVDa
Coronary artery disease 4533 4871 5231 5733 6084 6440 6607 6634
(17.4 %) (17.3 %) (17.3 %) (17.4 %) (17.4 %) (17.6 %) (17.8 %) (17.9 %)
Cerebral vascular disease 980 1045 1090 1161 1155 1147 1125 1088
(3.8 %) (3.7 %) (3.6 %) (3.5 %) (3.3 %) (3.1 %) (3.0 %) (2.9 %)
Diabetes 8143 8927 9976 11063 11906 12784 13223 13411
(31.3 %) (31.7 %) (32.9 %) (33.6 %) (34.1 %) (34.9 %) (35.7 %) (36.3 %)
Renal failure 1499 1737 1970 2331 2426 2587 2578 2511
(5.8 %) (6.2 %) (6.5 %) (7.1 %) (7.0 %) (7.1 %) (7.0 %) (6.8 %)
Peripheral vascular disease 249 256 269 288 317 330 332 325
(1.0 %) (0.9 %) (0.9 %) (0.9 %) (0.9 %) (0.9 %) (0.9 %) (0.9 %)
Hypertension 21,730 23,557 25,356 27,486 29,110 30,537 30,874 30,812
(83.4 %) (83.5 %) (83.7 %) (83.5 %) (83.4 %) (83.4 %) (83.3 %) (83.3 %)
aPercentages do not add up to 100 because patients can have more than one condition
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Discussion
Our analysis addressed several limitations of the original
IDOCC study [11]: we were able to (1) analyze population-
level data as opposed to a smaller sample of chart audit
data, (2) examine outcomes in a larger number of time
periods including post-intervention years to allow for the
possibility of slower uptake in best practices, and (3) focus
on CVD hospitalizations, a clinical outcome which may be
more relevant than the composite score.
We found a strong decreasing secular trend in CVD
hospitalizations, but no significant effect of the inter-
vention on hospitalizations in either intervention or
post-intervention years. These results cohere with the
previously published analysis, which used chart audit
data to evaluate the program’s impact on providers’ ad-
herence to recommended care guidelines as measured
by a composite score of eight indicators. The intervention
was found to decrease adherence to evidence-based guide-
lines by a statistically significant, but clinically insignifi-
cant, amount [11].
Other reasons for the lack of effect remain to be ex-
plored. One explanation is that the intended number of
face-to-face facilitator visits was not achieved. While 13
visits were planned for the first intervention year, on
average only 6.6 visits per year were made. The reasons
for this shortfall include: competing clinical priorities,
practice disruptions (i.e., system upgrades), a reduction in
the number of facilitators due to budget reductions and
the H1N1 outbreak which may have diverted resources.
A second explanation might be the “rising tide”
phenomenon whereby the same pressures that trigger
the development of a quality improvement intervention
also drive spontaneous, system-wide changes that lead
to across-the-board improvements [22]. In such cir-
cumstances, controlled evaluations may detect no in-
cremental benefit of the intervention. This explanation
is plausible given the clearly decreasing secular trend in
hospitalizations.
A third explanation may be the broad focus of the
intervention. In contrast to targeting a single disease,
IDOCC targeted guidelines for patients with a broad
number of cardiovascular-related conditions and risk
factors. This broad focus may have impeded practices’
ability to implement focused, system-level changes, or
may have diverted resources away from one area at the
expense of another. We are exploring these issues with
an in-depth qualitative study of participating practices.
A fourth explanation may be that we lacked study
power. We conducted no a-priori power calculations for
the secondary clinical outcomes, but given 70 participat-
ing practices (22 in step 1, and 24 in each of steps 2 and
3), an average of 180 patients per practice per year over
8 years, and an intracluster correlation coefficient of 0.001
(or coefficient of variation of 0.2), application of the power
formulas described by Hussey and Hughes (2007) [23]
showed that we had 82 % power to detect an OR of 0.76,
i.e., a reduction in CVD hospitalizations from a baseline
proportion of 25 per 1000 patients to 19 per 1000 patients.
Since these power formulas assumed an underlying model
with time specified as a categorical variable, we may have
been able to detect a slightly smaller difference using our
model with time as a simple linear term.
Our study had several strengths, including implemen-
tation across a large geographic area involving a diverse
range of practices, with outcomes assessed using admin-
istrative data for a substantial patient population. The
stepped wedge design allowed us to maintain a robust
randomized controlled trial model while offering the
intervention to all practices.
Our study also had some limitations. First, we had to
exclude from our analysis the 12 community health cen-
ters that underwent the IDOCC intervention as reliable
administrative information on this practice model was
not available for the entire study period. Second, we
were unable to identify patients at risk of CVD using the
same criteria as in the chart audit study, which included
smoking status and dyslipidemia, characteristics not easily
captured in administrative data, as risk factors. Restricting
the sample to those with confirmed CVD and then further
to those with diabetes (the most common and best iden-
tified disease with existing algorithms), did not change the
results. Third, we encountered several computational
challenges due to the sheer size of the datasets and the
complexity of the models. As a result, we were unable to
account for the correlation in repeated measures on the
same patients over time which decreased our ability to de-
tect any potential effect of the intervention.
Fig. 2 Observed cardiovascular disease (CVD) hospitalization rates
among all patients with, or at risk of, CVD
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Table 3 Primary outcome analysis of any cardiovascular disease (CVD) hospitalization using mixed-effects logistic regression analysis
accounting for clustering by practice and provider (N = 262,996)
Parameter Model A Model B Model C
(Unadjusted) (Adjusted for patient factors) (Adjusted for patient and provider factors)
Odds ratio p value Odds ratio p value Odds ratio p value
Phase
Baseline Ref Ref Ref
Intervention 0.96 0.51 0.96 0.50 0.96 0.49
Post 0.95 0.51 0.93 0.37 0.93 0.36
Year 0.95 <0.001 0.95 0.001 0.95 0.002
Region
1 1.54 0.04 1.13 0.49 0.87 0.41
2 0.89 0.48 0.90 0.43 0.75 0.028
3 1.08 0.65 0.99 0.94 0.81 0.09
4 1.36 0.07 1.01 0.93 0.74 0.035
5 0.84 0.34 0.90 0.50 0.85 0.22
6 0.87 0.51 0.95 0.75 0.89 0.47
7 0.80 0.18 0.81 0.11 0.72 0.011
8 0.95 0.81 0.92 0.65 0.83 0.24
9 Ref Ref Ref
Patient characteristics
Age 1.03 <0.001 1.03 <0.001
Sex 0.55 <0.001 0.55 <0.001
Number of ADGs
0 Ref - Ref -
1 (1–4) 0.78 0.18 0.78 0.19
2 (5–9) 1.16 0.44 1.16 0.42
3 (10+) 2.03 <0.001 2.04 <0.001
Location
Urban Ref - Ref -
Suburban 1.21 0.001 1.08 0.24
Rural 1.23 0.001 1.12 0.13
Income quintile
1 Ref - Ref -
2 0.89 0.015 0.90 0.020
3 0.86 0.002 0.86 0.002
4 0.80 <0.001 0.80 <0.001
5 0.75 <0.001 0.75 <0.001




Capitation, FHT 0.97 0.68
Capitation, non-FHT 1.07 0.13
Female physician 0.90 0.058
Years since graduation 1.00 0.24
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Fourth, due to practical and logistical constraints we
were unable to randomize individual practices. Random-
izing at a regional level led to some imbalances in the
characteristics of participants across steps. To the extent
that our adjusted analyses failed to capture these under-
lying differences, our estimates may be biased. Fifth, we
did not directly address the possibility of death in our
analysis. Recall that our outcome measure included any
patient who was hospitalized for CVD in each study
year, even if they subsequently died. Patients who died
without prior CVD hospitalizations would have contrib-
uted to the denominators for that year, but not the nu-
merators. To the extent that such patients are a biased
subsample of all patients with identical covariate values
Table 3 Primary outcome analysis of any cardiovascular disease (CVD) hospitalization using mixed-effects logistic regression analysis





Trained abroad 1.21 0.041
Practice size 1.02 0.054
ADG Aggregated Diagnostic Groups, FHT Family Health Team
Table 4 Pairwise least square mean comparisons between intervention conditions from primary outcome analysis and three
robustness analyses
Unadjusted Adjusted for patient characteristics Adjusted for patient and physician
OR 99 % CI p value OR 99 % CI P value OR 99 % CI P value
a) Primary outcome analysis: any CVD hospitalization (Yes/No) (N = 262,996)1
Post vs. intervention 0.98 0.86–1.12 0.73 0.96 0.85 − 1.10 0.48 0.96 0.84 − 1.10 0.46
Intervention vs. baseline 0.96 0.83 − 1.12 0.51 0.96 0.83 − 1.12 0.50 0.96 0.83 − 1.11 0.49
Post vs. baseline 0.95 0.76 − 1.18 0.51 0.93 0.75 − 1.15 0.37 0.93 0.74 − 1.15 0.36
Unadjusted Adjusted for patient characteristics Adjusted for patient and physician
RR 99 % CI p value RR 99 % CI p value RR 99 % CI p value
b) Number of CVD hospitalizations per year (N = 262,996)2
Post vs. intervention 0.99 0.84 − 1.19 0.99 0.97 0.82 − 1.15 0.72 0.97 0.83 − 1.15 0.76
Intervention vs. baseline 0.96 0.83 − 1.12 0.61 0.95 0.83 − 1.19 0.50 0.95 0.83 − 1.09 0.46
Post vs. baseline 0.96 0.72 − 1.28 0.78 0.92 0.71 − 1.21 0.57 0.93 0.71 − 1.21 0.56
Unadjusted Adjusted for patient characteristics Adjusted for patient and physician
OR 99 % CI p value OR 99 % CI p value OR 99 % CI P value
c) Primary outcome analysis of diabetic patient subsample (N = 89,433)3
Intervention vs. baseline 1.09 0.88 − 1.36 0.29 1.09 0.87 − 1.36 0.33 0.97 0.79 − 1.18 0.70
Post vs. baseline 1.11 0.80 − 1.54 0.40 1.07 0.77 − 1.49 0.58 1.09 0.87 − .36 0.34
Post vs. intervention 1.02 0.83 − 1.24 0.84 0.99 0.81 − 1.20 0.86 1.05 0.76 − 1.46 0.68
Unadjusted Adjusted for patient characteristics Adjusted for patient and physician
OR 99 % CI p value OR 99 % CI p value OR 99 % CI P value
d) Primary outcome analysis excluding patients only at risk of CVD (N = 132,686)4
Intervention vs. baseline 1.04 0.89 − 1.21 0.56 1.01 0.87 − 1.18 0.85 1.00 0.86 − 1.17 0.98
Post vs. baseline 1.06 0.89 − 1.25 0.42 1.05 0.89 − 1.25 0.44 1.05 0.88 − 1.25 0.44
Post vs. intervention 1.09 0.85 − 1.41 0.37 1.07 0.83 − 1.38 0.52 1.05 0.82 − 1.36 0.59
CI confidence interval. CVD cardiovascular disease. OR odds ratio. RR relative risk
1Mixed-effects logistic regression analysis, accounting for clustering by practice and provider
2Negative binomial regression analysis using robust standard errors accounting for clustering by practice
3Mixed-effects logistic regression analysis, accounting for clustering by practice and provider
4Mixed-effects logistic regression analysis, accounting for clustering by practice and provider
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who are at risk of hospitalization in any given year, our
parameter estimates may be biased (i.e., residual inform-
ative censoring).
Conclusion
IDOCC did not appear to significantly impact CVD hos-
pitalizations. Our findings form a more complete picture
of the (in)effectiveness of IDOCC and clarify that the
null result reported in the earlier paper was neither due
to choice of composite score outcome nor the relatively
short follow-up period [11]. PF is an expensive and
resource-intensive way to facilitate change in physician
behaviour, but—if effective—can create overall health
system savings [24]. As the popularity and expectation
of PF continues to grow, results from trials such as this
are crucial to understanding the scenarios under which
PF can be considered an efficient use of scare health care
resources.
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